Danaher (NYSE:DHR) Given New $205.00 Price Target at Wells Fargo & Company

Danaher (NYSE:DHR - Get Free Report) had its price objective lowered by analysts at Wells Fargo & Company from $210.00 to $205.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "equal weight" rating on the conglomerate's stock. Wells Fargo & Company's target price would indicate a potential downside of 0.29% from the company's previous close.

Several other analysts have also commented on the company. Leerink Partners raised their price objective on Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a report on Wednesday, April 23rd. Guggenheim reissued a "buy" rating and set a $250.00 price objective on shares of Danaher in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lowered their price objective on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. The Goldman Sachs Group reduced their target price on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Finally, UBS Group reduced their target price on Danaher from $275.00 to $240.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, Danaher has an average rating of "Moderate Buy" and a consensus target price of $247.61.

Danaher Stock Performance

DHR stock traded up $2.79 during trading on Wednesday, hitting $205.60. 5,355,676 shares of the company traded hands, compared to its average volume of 3,965,185. The stock's 50-day simple moving average is $196.38 and its 200 day simple moving average is $203.92. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.05. The company has a market cap of $147.22 billion, a PE ratio of 43.74, a P/E/G ratio of 2.82 and a beta of 0.77. Danaher has a 1 year low of $171.00 and a 1 year high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. Danaher's quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the business earned $1.72 earnings per share. On average, equities analysts expect that Danaher will post 7.63 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the transaction, the executive vice president owned 15,179 shares in the company, valued at $3,005,442. This trade represents a 51.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman directly owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Institutional Trading of Danaher

Several hedge funds have recently modified their holdings of the business. FAS Wealth Partners Inc. increased its stake in Danaher by 20.6% in the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after purchasing an additional 1,639 shares in the last quarter. Asahi Life Asset Management CO. LTD. purchased a new position in Danaher in the 1st quarter valued at approximately $539,000. Horizon Financial Services LLC increased its stake in Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after purchasing an additional 8,160 shares in the last quarter. Vision Capital Management Inc. purchased a new position in Danaher during the first quarter worth $461,000. Finally, Eos Management L.P. increased its position in Danaher by 55.8% during the first quarter. Eos Management L.P. now owns 40,567 shares of the conglomerate's stock worth $8,316,000 after buying an additional 14,537 shares in the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.